Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRC MARADC087 00 VP

Next Previous
X
Search
Drug Profile

VRC MARADC087 00 VP

Alternative Names: cAd3-Marburg vaccine; ChAd3-MARV; VRC-MARADC087-00-VP

Latest Information Update: 22 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; ReiThera
  • Developer National Institute of Allergy and Infectious Diseases; Sabin Vaccine Institute
  • Class Antivirals; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Marburg virus disease

Most Recent Events

  • 19 Dec 2023 Phase-II clinical trials in Marburg virus disease (Prevention) in Kenya (IM)
  • 19 Oct 2023 Phase-II clinical trials in Marburg virus disease (Prevention) in Uganda (IM)
  • 13 Jan 2023 Sabin Vaccine Institute receives grant under a development contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of VRC EBOADC069 00 VP and VRC MARADC087 00 VP

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top